Investor's Business Daily on MSN

Edwards, the 'cleanest large-cap medtech story,' reverses after quarterly beat

Edwards Lifesciences stock fell Friday, though the medtech company beat Wall Street's top- and bottom-line expectations.
Nasdaq

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...
Nasdaq

EDWARDS PASCAL PRECISION TRANSCATHETER MITRAL AND TRICUSPID VALVE REPAIR SYSTEM RECEIVES CE MARK

IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...

Edwards lifts 2026 sales growth outlook to 10%-11% while reaffirming $2.95-$3.05 EPS

Q2 2026 earnings call: sales +12.5%, raised FY guidance, TAVR/TMTT momentum, PROGRESS & NCD catalysts—read key takeaways.
Yahoo Finance

Does Edwards Lifesciences’ TAVR Momentum and PASCAL, EVOQUE Adoption Reinforce Its Moat (EW)?

Edwards Lifesciences recently announced it would report its first-quarter 2026 results on April 23, with early commentary highlighting continued momentum in its Transcatheter Aortic Valve Replacement ...
BioWorld

Edwards’ Pascal device shows well against Abbott’s Mitraclip at TCT

One of the biggest stories coming out of Transcatheter Cardiovascular Therapeutics’ annual meeting in Boston this weekend focuses on the success of Edwards Lifesciences Corp.’s freshly FDA-approved ...
BioWorld

Edwards’ Pascal reduces mitral regurgitation in 96% of CLASP IID participants

One-year results from the CLASP IID trial and registry showed outstanding results in patients with significant symptomatic degenerative mitral regurgitation (DMR) for Pascal, Edwards Lifesciences Corp ...